EASYRA HDL REAGENT; EASYRA LDL REAGENT; EASYRA CHOL REAGENT; EASYRA TRIG REAGENT
Device Facts
| Record ID | K111036 |
|---|---|
| Device Name | EASYRA HDL REAGENT; EASYRA LDL REAGENT; EASYRA CHOL REAGENT; EASYRA TRIG REAGENT |
| Applicant | Medica Corporation |
| Product Code | LBS · Clinical Chemistry |
| Decision Date | Jul 12, 2011 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 862.1475 |
| Device Class | Class 1 |
Indications for Use
The EasyRA HDL Cholesterol reagent is intended for the quantitative determination of High Density Lipoprotein Cholesterol in human serum and plasma on the Medica EasyRA Chemistry Analyzer. The Medica EasyRA HDL-Cholesterol reagent can assist in the diagnosis and treatment of patients at risk of developing coronary heart disease. For in vitro diagnostic use only. The EasyRA LDL Cholesterol reagent is intended for the quantitative determination of Low Density Lipoprotein Cholesterol in human serum and plasma, using the MEDICA "EasyRA Chemistry Analyzer" in clinical laboratories. The LDL Cholesterol measurements are used in the diagnosis and treatment of lipid disorders (such as diabetes mellitus), atherosclerosis, and various liver and renal diseases. For in vitro diagnostic use only. The EasyRA CHOL reagent is intended for the quantitative determination of total cholesterol in human serum and plasma, using the MEDICA "EasyRA Chemistry Analyzer" in clinical laboratories. Total cholesterol measurements are used to screen for elevated cholesterol as a risk factor in coronary artery disease. For in vitro diagnostic use only. The EasyRA TRIG reagent is intended for the quantitative measurement of triglycerides in human serum and plasma, using the MEDICA "EasyRA Chemistry Analyzer" in clinical laboratories. Measurements obtained by this device are used in the diagnosis and treatment of patients with diabetes mellitus, nephrosis, liver obstruction, other diseases involving lipid metabolism and various endocrine disorders. For in vitro diagnostic use only.
Device Story
In vitro diagnostic reagent systems for quantitative measurement of HDL-C, LDL-C, total cholesterol, and triglycerides; used on Medica EasyRA Chemistry Analyzer in clinical laboratories. Reagents are liquid, ready-to-use, packaged in wedge-shaped containers. HDL-C assay uses two-reagent system (R1/R2) to selectively remove non-HDL lipoproteins then solubilize HDL for chromogenic reaction. LDL-C assay uses two-reagent system to solubilize non-LDL particles, consume cholesterol, then solubilize LDL for chromogenic reaction. Total cholesterol uses enzymatic Trinder endpoint reaction (cholesterol esterase/oxidase/peroxidase) to produce red quinoneimine dye. Triglyceride assay uses lipase, glycerol kinase, and glycerol phosphate oxidase to produce red dye complex. Absorbance measured spectrophotometrically at specific wavelengths (520-600nm) proportional to analyte concentration. Output provides quantitative lipid levels to assist clinicians in diagnosing/treating metabolic and cardiovascular conditions.
Clinical Evidence
Bench testing only. Matrix comparison study performed using 63-70 paired serum and lithium heparin plasma samples per analyte. Regression analysis showed high correlation (R² 0.9950-0.9992) and slopes near 1.0. Precision studies (within-run and multi-day) confirmed CVs < 2% for all analytes in plasma. Extended linearity/dilution studies performed using spiked samples.
Technological Characteristics
Quantitative spectrophotometric assays. Reagents: liquid, ready-to-use, dual-chamber or single-chamber wedges. Detection: enzymatic endpoint reactions (Trinder for cholesterol; lipase/GPO for triglycerides; selective detergent for HDL/LDL). Wavelengths: 520nm, 550nm, 600nm. Connectivity: Medica EasyRA Chemistry Analyzer. Storage: 2-8°C.
Indications for Use
Indicated for quantitative determination of HDL-C, LDL-C, total cholesterol, and triglycerides in human serum and plasma to assist in diagnosis/treatment of lipid disorders, coronary heart disease, atherosclerosis, diabetes mellitus, and liver/renal diseases. Used in clinical laboratories on the Medica EasyRA Chemistry Analyzer.
Regulatory Classification
Identification
A lipoprotein test system is a device intended to measure lipoprotein in serum and plasma. Lipoprotein measurements are used in the diagnosis and treatment of lipid disorders (such as diabetes mellitus), atherosclerosis, and various liver and renal diseases.
Related Devices
- K972853 — CHOLESTEROL RAPID LIQUID REAGENT · Reagents Applications, Inc. · Sep 24, 1997
- K022772 — RAICHEM LDL-CHOLESTEROL DIRECT REAGENT · Hemagen Diagnostics, Inc. · Sep 17, 2002
Submission Summary (Full Text)
{0}
1
# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE
A. 510(k) Number:
k111036
B. Purpose for Submission:
The purpose of the submission is to add lithium heparin plasma as a sample matrix to the following previously cleared devices:
High Density Lipoprotein (HDL-Cholesterol) k073497
Low Density Lipoprotein (LDL-Cholesterol) k090734
Total Cholesterol (CHOL) k072249
Triglyceride (TRIG) k080823
C. Measurand:
HDL-Cholesterol, LDL-Cholesterol, Total Cholesterol, Triglyceride
D. Type of Test:
Quantitative spectrophotometric
F. Proprietary and Established Names:
EasyRA HDL Cholesterol Reagent, EasyRA LDL Cholesterol Reagent, EasyRA CHOL Reagent, EasyRA TRIG Reagent
E. Applicant:
Medica Corporation
G. Regulatory Information:
1. Regulation section:
| Device Name | Regulation | Name | Class | Product Code |
| --- | --- | --- | --- | --- |
| EasyRA HDL Cholesterol Reagent | 21 CFR§862.1475 | Lipoprotein test system | I, meets limitations per 21 CFR 862.9(c)(4) | LBS |
{1}
| EasyRA LDL Cholesterol Reagent | 21 CFR§862.1475 | Lipoprotein test system | I, meets limitations per 21 CFR 862.9(c)(4) | MRR |
| --- | --- | --- | --- | --- |
| EasyRA CHOL Reagent | 21 CFR§862.1175 | Cholesterol (total) test system | I, meets limitations per 21 CFR 862.9(c)(4) | CHH |
| EasyRA TRIG Reagent | 21 CFR§862.1705 | Triglyceride test system | I, meets limitations per 21 CFR 862.9(c)(4) | CDT |
4. Panel:
Chemistry (75)
H. Intended Use:
1. Intended use(s):
See Indications for use below.
2. Indication(s) for use:
EasyRA High Density Lipoproteins (HDL) Cholesterol Reagent:
The EasyRA HDL Cholesterol reagent is intended for the quantitative determination of High Density Lipoprotein Cholesterol in human serum and plasma on the Medica EasyRA Chemistry Analyzer. The Medica EasyRA HDL-Cholesterol reagent can assist in the diagnosis and treatment of patients at risk of developing coronary heart disease. For in vitro diagnostic use only.
EasyRA Low Density Lipoproteins (LDL) cholesterol Reagent
The EasyRA LDL Cholesterol reagent is intended for the quantitative determination of Low Density Lipoprotein Cholesterol in human serum and plasma, using the MEDICA "EasyRA Chemistry Analyzer" in clinical laboratories. The LDL Cholesterol measurements are used in the diagnosis and treatment of lipid disorders (such as diabetes mellitus), atherosclerosis, and various liver and renal diseases. For in vitro diagnostic use only.
EasyRA Cholesterol (CHOL) Reagent
The EasyRA CHOL reagent is intended for the quantitative determination of total cholesterol in human serum and plasma, using the MEDICA "EasyRA Chemistry Analyzer" in clinical laboratories. Total cholesterol measurements are used to screen for elevated cholesterol as a risk factor in coronary artery disease. For in vitro diagnostic use only.
{2}
3
EasyRA Triglycerides (TRIG) Reagent
The EasyRA TRIG reagent is intended for the quantitative measurement of triglycerides in human serum and plasma, using the MEDICA “EasyRA Chemistry Analyzer” in clinical laboratories. Measurements obtained by this device are used in the diagnosis and treatment of patients with diabetes mellitus, nephrosis, liver obstruction, other diseases involving lipid metabolism and various endocrine disorders. For in vitro diagnostic use only.
3. Special conditions for use statement(s):
For prescription use
4. Special instrument requirements:
Medica EasyRA chemistry analyzer
I. Device Description:
The Medica HDL cholesterol reagent and the LDL reagents are in vitro diagnostic reagent systems consisting of two parts: R1 and R2. The reagents are packaged in wedge shaped containers and are liquid, ready-to-use.
The Medica Cholesterol and Triglyceride reagents are single in vitro diagnostic reagent systems. Each reagent is packaged in a wedge shaped container and is liquid, ready-to-use.
J. Substantial Equivalence Information:
1. Predicate device name(s):
| Device Name | Predicate 510k | Predicate Name |
| --- | --- | --- |
| EasyRA HDL Reagent | k073497 | EasyRA HDL Reagent |
| EasyRA LDL Reagent | k090734 | EasyRA LDL Reagent |
| EasyRA CHOL Reagent | k072249 | EasyRA CHOL Reagent |
| EasyRA TRIG Reagent | k080823 | EasyRA TRIG Reagent |
{3}
3. Comparison with predicate:
| HDL-Cholesterol | | |
| --- | --- | --- |
| Item | Device | Predicate-k073497 |
| Intended Use | Same | The EasyRA High Density Lipoprotein (HDL) reagent is intended for the quantitative determination of High Density Lipoproteins using the MEDICA “EasyRA Chemistry Analyzer” in clinical laboratories. |
| Sample | Serum, Plasma | Serum |
| Reagent type | Same | Liquid ready-for-use |
| Reportable range | Same | 2.0 – 150 mg/dL |
| Wavelength | Same | Primary: 600 nm Secondary: 700 nm |
| Wavelength | Same | Primary: 600 nm Secondary: 700 nm |
| Reagent storage | Same | 2 – 8 °C |
| Test Summary | Same | The HDL-cholesterol reagent 1 precipitates non-high density lipoproteins. The HDL-cholesterol reagent 2 solubilizes and reacts with HDL to develop a chromogen absorbing at 600nm. The absorbance is directly proportional to the HDL level. |
| -LDL-Cholesterol | | |
| --- | --- | --- |
| Item | Device | Predicate- k090734 |
| Intended Use | Same | The EasyRA Low Density Lipoprotein (LDL-cholesterol) reagent is intended for the quantitative determination of Low Density Lipoproteins using the MEDICA “EasyRA Chemistry Analyzer” in clinical laboratories. |
| Sample | Serum, Plasma | Serum |
| Reagent type | Same | Liquid ready-for-use |
| Reportable range | Same | 6.0 – 540 mg/dL |
| Wavelength | Same | 550 nm |
| Reaction type | Same | Endpoint |
| Reagent storage | Same | 2 – 8 °C |
| Test Summary | Same | Reagent 1 solubilizes only the non LDL particles. The cholesterol realized is consumed by cholesterol esterase/oxidase in a non color forming reaction. Reagent 2 solubilizes the LDL particles and a coupler develops a chromogen that absorbs light at |
{4}
5
| -LDL-Cholesterol | | |
| --- | --- | --- |
| Item | Device | Predicate- k090734 |
| | | 550nm. The EasyRA measures absorbance according to Beer’s law. |
| -Total Cholesterol | | |
| --- | --- | --- |
| Item | Device | Predicate- k072249 |
| Intended Use | Same | The EasyRA (CHOL) reagent is intended for the quantitative determination of Total Cholesterol using the MEDICA “EasyRA Chemistry Analyzer” in clinical laboratories. |
| Sample | Serum, Plasma | Serum |
| Reagent type | Same | Liquid ready-for-use |
| Reportable range | Same | 10 – 600 mg/dL |
| Wavelength | Same | 520 nm |
| Reaction type | Same | Endpoint |
| Reagent storage | Same | 2 – 8 °C |
| Test Summary | Same | Cholesterol esters are hydrolyzed to cholesterol and fatty acids. Cholesterol is oxidized to delta 4-cholestenone with the simultaneous production of hydrogen peroxide. In the presence of peroxidase, hydrogen peroxide oxidizes phenol and 4-aminoantipyrine to give a quinoneimine dye colored red. The intensity of the color produced is proportional to the concentration of cholesterol in the sample. |
| Triglyceride | | |
| --- | --- | --- |
| Item | Device | Predicate- k080823 |
| Intended Use | Same | The EasyRA TRIG reagent is intended for the quantitative determination of Triglycerides using the MEDICA “EasyRA Chemistry Analyzer” in clinical laboratories. |
| Sample | Serum, Plasma | Serum |
| Reagent type | Same | Liquid ready-for-use |
| Reportable range | Same | 3 – 750 mg/dL |
| Wavelength | Same | 520 nm |
| Reaction type | Same | Endpoint |
| Reagent storage | Same | 2 – 8 °C |
| Test Summary | Same | Triglycerides are hydrolyzed to glycerol and free fatty acids by lipase. The |
{5}
| Triglyceride | | |
| --- | --- | --- |
| Item | Device | Predicate- k080823 |
| | | glycerol is phosphorylated to glycerol-1-phosphate, which is then oxidized by glycerol phosphate oxidase (GPO) to produce hydrogen peroxide. The hydrogen peroxide causes oxidative coupling of p-chlorophenol and 4 amino-antipyrine, which produces a red dye complex. The absorbance of the dye at 520 nm is proportional to the concentration of triglyceride in the sample. |
## K. Standard/Guidance Document Referenced (if applicable):
CLSI EP5-A2: Evaluation of Precision Performance of Quantitative Measurement Methods
CLSI EP9-A2: Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline – Second Edition
## L. Test Principle:
HDL-C: The Medica HDL cholesterol assay is a two reagent system: R1 and R2. The first step involves the removal of non-high density lipoproteins (non-HDL) via selective reaction with reagent R1. In the second step, the selective detergent in R2 solubilizes the HDL cholesterol, which then reacts with a chromogen to develop a color that can be read optically at 600nm. The intensity of the color is proportional to the concentration of HDL cholesterol in the sample.
LDL-C: The Medica Low Density Lipoprotein (LDL) Reagent is provided in a ready-to-use dual chamber plastic wedge. Reagent 1 solubilizes the non-LDL particles. The cholesterol realized is consumed by cholesterol esterase and cholesterol oxidase in a non color forming reaction. Reagent 2 solubilizes the LDL particles and a chromogenic coupler develops a chromogen. The chromogen absorbs light of specific wavelength (550nm), where the EasyRA measures absorbance according to Beer’s law.
Cholesterol (CHOL): The Medica EasyRA Cholesterol reagent uses the enzymatic Trinder endpoint reaction, which is based on the work of Allain et al. In this method, cholesterol esters are hydrolyzed by cholesterol esterase to cholesterol and fatty acids. Cholesterol is oxidized by cholesterol oxidase to delta 4-cholestenone with the simultaneous production of hydrogen peroxide. In the
{6}
presence of peroxidase, hydrogen peroxide oxidizes phenol and 4-aminoantipyrine to give a quinoneimine dye colored red. The absorbance of the resulting quinoneimine dye is measured at $520\mathrm{nm}$ with $600\mathrm{nm}$ as a blanking wavelength. The intensity of the color produced is proportional to the concentration of cholesterol in the sample based on Beer's Law.
Triglyceride: The Medica EasyRA TRIG Reagent is provided in a ready-to-use plastic wedge. Serum triglycerides are hydrolyzed to glycerol and free fatty acids by lipase. In the presence of ATP and glycerol kinase (GK), the glycerol is phosphorylated to glycerol-1-phosphate, which is then oxidized by glycerol phosphate oxidase (GPO) to produce hydrogen peroxide. The hydrogen peroxide causes oxidative coupling of p-chlorophenol and 4 amino-antipyrine, which produces a red colored quinoneimine dye complex. The absorbance of the dye at $520\mathrm{nm}$ is proportional to the concentration of triglyceride in the sample according to Beer's Law.
# M. Performance Characteristics (if/when applicable):
# 1. Analytical performance:
# a. Precision/Reproducibility:
Serum and plasma- Precision studies were performed on the EasyRA analyzer in conjunction with the matrix comparison study with lithium heparin tubes. Paired plasma and serum samples were analyzed over a minimum of 7 days. Results were calculated for average SD for 3 partitioned bins covering the ranges tested. The average SD in each of the 3 bins for both plasma and serum are comparable.
| HDL- cholesterol | Low | Medium | High |
| --- | --- | --- | --- |
| Analytical Range | 2 - 45 mg/dL | 45 – 60 mg/dL | 60– 150 mg/dL |
| Number of samples | 20 | 29 | 18 |
| Number of replicates | 2 | 2 | 2 |
| Serum Mean | 34.3 | 52.1 | 86.3 |
| Serum SD | 0.50 | 0.44 | 0.53 |
| Serum CV (%) | 1.46% | 0.84% | 0.61% |
| Plasma Mean | 33.9 | 51.6 | 84.0 |
| Plasma SD | 0.63 | 0.60 | 0.83 |
| Plasma CV (%) | 1.86% | 1.17% | 0.99% |
| LDL- cholesterol | Low | Medium | High |
| --- | --- | --- | --- |
| Analytical Range | 6 - 100 mg/dL | 100 – 130 mg/dL | 130– 540 mg/dL |
| Number of samples | 28 | 21 | 19 |
| Number of replicates | 2 | 2 | 2 |
{7}
| Total Cholesterol | Low | Medium | High |
| --- | --- | --- | --- |
| Analytical Range | 10 - 175 mg/dL | 175 - 210 mg/dL | 210- 600 mg/dL |
| Number of samples | 29 | 20 | 21 |
| Number of replicates | 2 | 2 | 2 |
| Serum Mean | 140.0 | 191.8 | 297.2 |
| Serum SD | 1.32 | 1.79 | 4.15 |
| Serum CV (%) | 0.95% | 0.93% | 1.40% |
| Plasma Mean | 136.4 | 189.3 | 295.1 |
| Plasma SD | 1.26 | 1.29 | 4.63 |
| Plasma CV (%) | 0.92% | 0.68% | 1.57% |
| Triglyceride | Low | Medium | High |
| --- | --- | --- | --- |
| Analytical Range | 3 - 100 mg/dL | 100 - 150 mg/dL | 150- 750 mg/dL |
| Number of samples | 22 | 17 | 24 |
| Number of replicates | 2 | 2 | 2 |
| Serum Mean | 72.0 | 122.0 | 285.2 |
| Serum SD | 0.71 | 1.10 | 1.66 |
| Serum CV (%) | 0.98% | 0.90% | 0.58% |
| Plasma Mean | 68.6 | 117.5 | 275.9 |
| Plasma SD | 0.95 | 0.92 | 1.75 |
| Plasma CV (%) | 1.39% | 0.79% | 0.63% |
In addition a simplified within-run precision study was performed on the EasyRA analyzer by analyzing 3 plasma patient samples, 20 consecutive times in one run on one day. The within-run precision data is summarized in the table below:
| | Mean | SD | CV (%) |
| --- | --- | --- | --- |
| HDL-C | Level 1 – 25.9 | Level 1 – 0.31 | Level 1 – 1.19 |
| | Level 2 – 54 | Level 2 – 0.65 | Level 2 – 1.20 |
| | Level 3 – 133.2 | Level 3 – 0.89 | Level 3 – 0.67 |
| LDL-C | Level 1 – 36.9 | Level 1 – 0.49 | Level 1 – 1.33 |
| | Level 2 – 93.2 | Level 2 – 1.18 | Level 2 – 1.27 |
| | Level 3 – 287.7 | Level 3 – 1.84 | Level 3 – 0.64 |
| Cholesterol | Level 1 – 43.0 | Level 1 – 0.51 | Level 1 – 1.19 |
| | Level 2 – 154.9 | Level 2 – 1.60 | Level 2 – 1.03 |
{8}
9
b. Linearity/assay reportable range:
Plasma - Linearity studies were not conducted in plasma. See previously cleared linearity data in k073497 (HDL-C), k090734 (LDL-C), k072249 (Chol), and k080823 (Triglyceride) for serum samples. The linear reportable ranges for each assay are summarized below.
| Device Name | Measuring Range |
| --- | --- |
| EasyRA HDL-C Reagent | 2 – 150 mg/dL |
| EasyRA LDL-C Reagent | 6 to 540 mg/dL |
| EasyRA CHOL Reagent | 10 – 600 mg/dL |
| EasyRA TRIG Reagent | 3 mg/dL to 750 mg/dL |
Extended linearity studies were performed for LDL, cholesterol and triglyceride to evaluate accuracy and precision. The sponsor recommends a dilution of 1:2 when the LDL-C, cholesterol and triglyceride results in plasma or serum fall outside the upper measuring range of 540 mg/dL, 600 mg/dL and 750 mg/dL, respectively. A dilution study was performed for LDL-C, cholesterol and triglyceride on five different spiked patient plasma samples (one set of 5 for each assay) to increase the LDL level in the range of 540 to 1080 mg/dL, to increase the cholesterol level in the range of 600 to 1200 mg/dL, and to increase triglyceride level in the range from 750 to 1500 mg/dL. Materials used for spiking for LDL-C and cholesterol were derived from bovine material. High triglyceride levels were obtained by spiking with Intralipid.
Each sample was then diluted with saline at 1:2 dilution by the analyzer and compared to a manually diluted sample. Each diluted sample was run in triplicate on two EasyRA analyzers. The % recovery range of the system for each analyte is provided in the table below:
| Device Name | EasyRA % Recovery |
| --- | --- |
| EasyRA LDL-C Reagent | 99.38-101.4 % |
| EasyRA CHOL Reagent | 101.5-102.9 % |
| EasyRA TRIG Reagent | 97.7-104.8 % |
In addition, a simplified within-run precision study was performed in the extended linearity range for all analytes by analyzing 3 plasma samples, 20 consecutive times in one run on one day on three instruments using on-board dilution. The within-run precision data is summarized in the table below:
{9}
| | Mean | SD | CV (%) |
| --- | --- | --- | --- |
| LDL-C | Level 1 – 631.5 | Level 1 – 7.37 | Level 1 – 1.17 |
| | Level 2 – 696.4 | Level 2 – 8.8 | Level 2 – 1.26 |
| | Level 3 – 837.0 | Level 3 – 8.76 | Level 3 – 1.05 |
| Cholesterol | Level 1 – 711.3 | Level 1 – 6.72 | Level 1 – 0.94 |
| | Level 2 – 814.5 | Level 2 – 15.3 | Level 2 – 1.87 |
| | Level 3 – 916.8 | Level 3 – 11.1 | Level 3 – 1.21 |
| Triglyceride | Level 1 – 893.2 | Level 1 – 6.99 | Level 1 – 0.78 |
| | Level 2 – 1014.0 | Level 2 – 17.84 | Level 2 – 1.76 |
| | Level 3 – 1355.3 | Level 3 – 7.53 | Level 3 – 0.56 |
c. Traceability, Stability, Expected values (controls, calibrators, or methods):
Calibrators were previously cleared under k073497 (HDL-C), k090734 (LDL-C), k072249 (Total Cholesterol), k080823 (Triglyceride).
The Easy RA HDL-C, LDL-C and Total Cholesterol devices are not CRMLN certified.
d. Detection limit:
Limit of detection studies were not conducted for plasma. See cleared serum data under k073497 (HDL-C), k090734 (LDL-C), k072249 (Total Cholesterol), k080823 (Triglyceride).
e. Analytical specificity:
Interference studies were not conducted for plasma. See cleared serum data under k073497 (HDL-C), k090734 (LDL-C), k072249 (Total Cholesterol), k080823 (Triglyceride).
f. Assay cut-off:
Not applicable.
2. Comparison studies:
a. Method comparison with predicate device:
Serum—See cleared method comparison data under k073497 (HDL-C), k090734 (LDL-C), k072249 (Total Cholesterol), k080823 (Triglyceride). Plasma matrix comparison data are provided below in 2. (b) of this section.
b. Matrix comparison:
{10}
Lithium Heparin Plasma - A matrix comparison study was performed in conjunction with CLSI EP9-A2 guidelines using lithium heparin tubes. The study was conducted with human plasma and serum samples. Each sample was evaluated for bias and recovery between the two matrices using the EasyRA chemistry analyzer. 67 paired samples (57 natural and 10 altered through spiking or dilution) were used for HDL-C; 68 paired samples (57 natural and 11 altered through spiking or dilution) were used for LDL-C; 70 paired samples (57 natural and 13 altered through spiking or dilution) were used for cholesterol; and 63 paired samples (56 natural and 7 altered through spiking or dilution) were used for triglyceride. One single set of plasma samples were used as test samples, while duplicate serum samples were used as references. The follow regression equations were obtained:
| Analyte | Slope | Intercept | R² | Sample Range (mg/dL) |
| --- | --- | --- | --- | --- |
| HDL-C | 0.9767 | 0.0900 | 0.9950 | 3 to 148 |
| LDL-C | 0.9954 | -1.8888 | 0.9991 | 9 to 512 |
| Cholesterol | 1.0145 | -5.1408 | 0.9982 | 11 to 578 |
| Triglyceride | 0.9735 | -1.9025 | 0.9992 | 8 to 706 |
3. Clinical studies:
a. Clinical Sensitivity:
Not applicable.
b. Clinical specificity:
Not applicable.
c. Other clinical supportive data (when a. and b. are not applicable):
Not applicable.
4. Clinical cut-off:
Not applicable.
5. Expected values/Reference range:
All reference ranges in the labeling follow the recommendations set by the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) guidelines as follows:
HDL-Cholesterol¹: < 40 mg/dL Low, ≥ 60 mg/dL High
LDL-Cholesterol¹:
{11}
LDL Cholesterol – Primary Target of Therapy
<100 mg/dL Optimal
100-129 mg/dL Near optimal/above optimal
130-159 mg/dL Borderline high
160-189 mg/dL High
>190 mg/dL Very high
**Cholesterol¹:**
| Risk Classification | Total Cholesterol |
| --- | --- |
| Desirable | < 200 mg/dl
(5.18 mmol/L) |
| Borderline High | 200 –239 mg/dl
(5.18-6.19 mmol/L) |
| High | ≥ 240 mg/dl
(6.22mmol/L) |
**Triglyceride¹:**
| Triglycerides | Primary Target of Therapy |
| --- | --- |
| <150 mg/dL | Normal |
| 150-199 mg/dL | Borderline High |
| 200-499 mg/dL | High |
| >500 mg/dL | Very High |
¹ Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). NIH publication No. 01-3670: May 2001.
**N. Proposed Labeling:**
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.
**O. Conclusion:**
The submitted information in this premarket notification is complete and supports a substantial equivalence decision.
